All In MedTech

FDA Clearance Tracker · P110008-S013

coflex Interlaminar Stabilization Device

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Mar 31, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Mar 31, 2021

Approved

Time to decision

84 days

Received Jan 6, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track No User Fee

Device class

Class III

The decision

FDA number
P110008-S013
Device name
coflex Interlaminar Stabilization Device
Applicant location
Merignac Gironde
Received
Jan 6, 2021
Decided
Mar 31, 2021
Decision
Approved
Supplement type
Normal 180 Day Track No User Fee
Reason for supplement
Postapproval Study Protocol
Original approval
P110008

Device type

Device class
Class III

Every decision under product code NQO

FDA's approval statement

As written in FDA's record.

Approval of the revised protocol for the post-approval study (PAS) protocol.

Source documents

Other decisions for Companion Spine France

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

1 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.